stockrowLigand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024.
- Revenue
- −31.8%
- EPS
- −123.9%
- Free cash flow
- −268.5%
- Total debt
- +52.6%
Quarter to September 2026, against a year earlier
Follow LGND
Alert me
Ligand Pharmaceuticals Incorporated (LGND) Gross margin
Ligand Pharmaceuticals Incorporated's gross margin over the twelve months to 30 September 2026 was 95.2%, up 0.7 percentage points from fiscal 2025 (94.6%). Over the past ten years it has ranged from 73.1% (fiscal 2022) to 97.5% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 94.6% | 1.20 |
| FY2024 | 93.4% | 1.38 |
| FY2023 | 92.0% | 18.91 |
| FY2022 | 73.1% | (1.18) |
| FY2021 | 74.3% | (7.14) |
| FY2020 | 81.4% | (9.17) |
| FY2019 | 90.6% | (6.91) |
| FY2018 | 97.5% | 1.28 |
| FY2017 | 96.2% | 1.31 |
| FY2016 | 94.9% | 2.96 |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Sep 2026 | 96.6% | 1.68 |
| Jun 2026 | 95.0% | 1.28 |
| Mar 2026 | 93.7% | (1.32) |
| Dec 2025 | 95.0% | (1.72) |
| 43 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. compare | 98.2% |
| LGND Ligand Pharmaceuticals Incorporated | 95.2% |
| PTCT PTC Therapeutics, Inc. compare | 93.2% |
| MIRM Mirum Pharmaceuticals, Inc. compare | 81.7% |
| KOD Kodiak Sciences Inc. compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | 0.00% |
| IMVT Immunovant, Inc. compare | 0.00% |
| CGON CG Oncology, Inc. compare | −85.2% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on LGND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement